ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
-0,61%
Bitcoin
69 336,38
-2,02%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Design Therapeutics Inc (DSGN)

  7. Design Therapeutics Inc (DSGN) Actualités

DSGN

Design Therapeutics (DSGN)

Design Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DSGN
DateHeureSourceTitreSymboleSociété
08/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
08/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
08/05/202422h05GlobeNewswire Inc.Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesNASDAQ:DSGNDesign Therapeutics Inc
07/05/202412h30GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
19/03/202421h01GlobeNewswire Inc.Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:DSGNDesign Therapeutics Inc
12/03/202411h30GlobeNewswire Inc.Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateNASDAQ:DSGNDesign Therapeutics Inc
05/01/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
13/11/202322h05GlobeNewswire Inc.Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024NASDAQ:DSGNDesign Therapeutics Inc
06/09/202323h13Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DSGNDesign Therapeutics Inc
14/08/202322h05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/08/202322h01GlobeNewswire Inc.Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaNASDAQ:DSGNDesign Therapeutics Inc
02/06/202322h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DSGNDesign Therapeutics Inc
01/06/202322h46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DSGNDesign Therapeutics Inc
31/05/202312h30GlobeNewswire Inc.Design Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
09/05/202322h05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
24/04/202312h30GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023NASDAQ:DSGNDesign Therapeutics Inc
13/04/202322h41Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DSGNDesign Therapeutics Inc
03/04/202322h56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202321h27Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202321h05GlobeNewswire Inc.Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/02/202314h16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DSGNDesign Therapeutics Inc
08/02/202312h30GlobeNewswire Inc.Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceNASDAQ:DSGNDesign Therapeutics Inc
22/12/202222h26Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:DSGNDesign Therapeutics Inc
08/12/202214h01TipRanksDesign Therapeutics Tanks Even After Positive Clinical DataNASDAQ:DSGNDesign Therapeutics Inc
07/12/202222h01GlobeNewswire Inc.Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressNASDAQ:DSGNDesign Therapeutics Inc
03/11/202221h05GlobeNewswire Inc.Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
17/10/202222h05GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022NASDAQ:DSGNDesign Therapeutics Inc
22/09/202212h30GlobeNewswire Inc.Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine SummitNASDAQ:DSGNDesign Therapeutics Inc
17/08/202203h48TipRanksRBC Capital Sticks to Its Buy Rating for Design Therapeutics (DSGN)NASDAQ:DSGNDesign Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DSGN

Dernières Valeurs Consultées

NYSE
KO
Coca Cola
EU
PX1
CAC 40
NYSE
NKE
Nike
EU
EN
Bouygues
COIN
ETHUSD
Ethereum
EU
HO
Thales
EU
RNO
Renault
NYSE
DIS
Walt Disney
EU
BEL20
Bel 20
EU
BNP
BNP Paribas
NASDAQ
MSFT
Microsoft
FTSE
UKX
FTSE 100
NYSE
JPM
JP Morgan Chase
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés